AFDN and acute myeloid leukemia: Interestingly, MLL-AF6 AML Sharp1−/− cells demonstrated significant reduction both in L-GMP and LSK populations compared to Sharp1+/+ (Sharp1+/+ vs Sharp1−/−; 0.50 vs 0.18 %, p < 0.05 and 0.77 vs 0.24 %, p < 0.05, respectively) (Fig. 5a).